Your browser doesn't support javascript.
loading
Treatment related factors associated with the risk of breast radio-induced-sarcoma.
Mirjolet, Céline; Diallo, Ibrahima; Bertaut, Aurélie; Veres, Cristina; Sargos, Paul; Helfre, Sylvie; Sunyach, Marie-Pierre; Truc, Gilles; Le Pechoux, Cécile; Paumier, Amaury; Ducassou, Anne; Jolnerovski, Maria; Thariat, Juliette; Lapeyre, Michel; Cordoba, Abel; Mahé, Marc-André; Maingon, Philippe.
Afiliación
  • Mirjolet C; Radiation Oncology Department, Georges François Leclerc Cancer Center, Unicancer, Dijon, France; INSERM 1231, Cadir Team, Dijon, France.
  • Diallo I; Dosimetry Platform, Unit 1018 INSERM-CESP, Villejuif, France; Radiation Oncology Department, Gustave Roussy, Unicancer, Villejuif, France; Université Paris-Saclay, Villejuif, France.
  • Bertaut A; Department of Methodology, Biostatistics and Data Management, Georges François Leclerc Cancer Center, Unicancer, Dijon, France.
  • Veres C; Radiation Oncology Department, Gustave Roussy, Unicancer, Villejuif, France.
  • Sargos P; Radiation Oncology Department, Institut Bergonié, Unicancer, Bordeaux, France.
  • Helfre S; Radiation Oncology Department, Institut Curie, Unicancer, Paris, France.
  • Sunyach MP; Radiation Oncology Department, Centre Léon Bérard, Unicancer, Lyon, France.
  • Truc G; Radiation Oncology Department, Georges François Leclerc Cancer Center, Unicancer, Dijon, France.
  • Le Pechoux C; Radiation Oncology Department, Gustave Roussy, Unicancer, Villejuif, France.
  • Paumier A; Radiation Oncology Department, Institut de Cancérologie de l'Ouest, Unicancer, Anger, France.
  • Ducassou A; Radiation Oncology Department, IUCT Oncopole, Toulouse, France.
  • Jolnerovski M; Radiation Oncology Department, Institut de Cancérologie de Lorraine, Unicancer, Vandoeuvre-les-Nancy, France.
  • Thariat J; Radiation Oncology Department, Centre Antoine Lacassagne, Unicancer, Nice, France; Radiation Oncology Department, Centre François Baclesse, Unicancer, Caen, France.
  • Lapeyre M; Radiation Oncology Department, Centre Jean-Perrin, Unicancer, Clermont-Ferrand, France.
  • Cordoba A; Radiation Oncology Department, Centre Oscar Lambret, Unicancer, Lille, France.
  • Mahé MA; Radiation Oncology Department, Centre François Baclesse, Unicancer, Caen, France.
  • Maingon P; Radiation Oncology Department, Georges François Leclerc Cancer Center, Unicancer, Dijon, France; Sorbonne University, APHP. Sorbonne University, Radiation Oncology Department, GHU La Pitié Salpêtrière, Paris, France. Electronic address: philippe.maingon@aphp.fr.
Radiother Oncol ; 171: 14-21, 2022 06.
Article en En | MEDLINE | ID: mdl-35405175
ABSTRACT
BACKGROUND AND

PURPOSE:

The Radiation Induced Sarcoma (RIS) is a rare but serious adverse event following radiotherapy (RT). Current RT techniques are more precise, but irradiate a larger volume at a low dose. This study aimed to describe radiation characteristics in a large series of patients suffering from RIS. MATERIALS AND

METHODS:

Patient-representative voxel-based anthropomorphic phantoms were used to reconstruct patient-specific RT fields for 125 patients diagnosed with RIS after primary breast cancer. For each patient, the location of the RIS onset site was determined and transferred onto the phantom as a contour. Using a treatment planning system (TPS), the dose distribution on the RIS in the phantom was calculated.

RESULTS:

The mean dose (Dmean) received in the area where RIS subsequently developed was 47.8 ± 11.6 Gy. The median dose in the zones where RIS later developed ranged from 11 Gy to 58.8 Gy. The median time from RT to RIS development was 8 years (range 2-32 years). Analysis for predictors of time to radiation-induced sarcoma development highlighted a significant impact of age of patient during the RT whereas in multivariable analysis chemotherapy and hormonotherapy for primary breast cancer were not associated with a significant difference in time to diagnosis of RIS.

CONCLUSIONS:

This study highlights that the dose received by the tissue in which the RIS developed was almost 47 Gy. These results are encouraging for the use of new RT techniques increasing volumes receiving low doses, without fear of an excess of RIS over the next 10 years.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sarcoma / Neoplasias de los Tejidos Blandos / Neoplasias de la Mama Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Radiother Oncol Año: 2022 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sarcoma / Neoplasias de los Tejidos Blandos / Neoplasias de la Mama Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Radiother Oncol Año: 2022 Tipo del documento: Article País de afiliación: Francia